APWM
NTLA icon

Atlas Private Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Atlas Private Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-676
Closed -$14K – 448
2020
Q2 		$14K Hold
676
– – 0.01% 303
2020
Q1 		$8K Hold
676
– – 0.01% 329
2019
Q4 		$10K Buy
+676
New +$9.41K 0.01% 348

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Atlas Private Wealth Management's NTLA Position: Q3 2020 in Review

Atlas Private Wealth Management sold out of Intellia Therapeutics (NTLA) in Q3 2020, closing a stake of 676 shares — an estimated $14K sold.

Atlas Private Wealth Management first reported a position in NTLA in Q4 2019 and held it in 3 quarters. The position peaked at $14K in Q2 2020. 165 funds tracked by Wall St. Rank hold NTLA as of Q3 2020.

  • Atlas Private Wealth Management reported no remaining Intellia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Atlas Private Wealth Management sold 676 Intellia Therapeutics shares in Q3 2020, an estimated $14K.
  • Atlas Private Wealth Management first reported a position in Intellia Therapeutics in Q4 2019 and held it in 3 quarters.
  • Atlas Private Wealth Management's Intellia Therapeutics position peaked at $14K in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2020.

Based on Atlas Private Wealth Management's 13F filing for Q3 2020, filed 5 Nov 2020.